CIK 1281446
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 89.08% | 35 |
| Unclassified | 10.92% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics, Inc. | Health Care | 7.71% |
| 2 | VOR | Vor Biopharma Inc. | Health Care | 7.65% |
| 3 | ZURA | Zura Bio Ltd | Health Care | 6.14% |
| 4 | AMLX | Amylyx Pharmaceuticals, Inc. | Health Care | 5.96% |
| 5 | NKTR | NEKTAR THERAPEUTICS | Health Care | 5.58% |
| 6 | SLGL | SOL GEL TECHNOLOGIES | Unclassified | 5.32% |
| 7 | ALMS | ALUMIS INC. | Health Care | 4.62% |
| 8 | DRUG | BRIGHT MINDS BIOSCIENCES INC. | Health Care | 3.93% |
| 9 | ANNX | Annexon, Inc. | Health Care | 3.39% |
| 10 | KALVISTA PHARMACEUTICALS INC | Unclassified | 3.33% |
35/39 names classified · sector 89.1% of weight · industry 89.1% · mkt cap 85.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 89.1% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.4% of book weight (1/39 names) · unclassified 99.6%: APGE, VOR, ZURA, AMLX, NKTR, SLGL, ALMS, DRUG, ANNX, +28 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | APGEAPOGEE THERAPEUTICS INC | 374,000 | $31M | 7.7% | HOLD |
| 2 | VORVOR BIOPHARMA INC | 1,750,000 | $31M | 7.6% | ADD 28% |
| 3 | ZURAZURA BIO LTD | 4,215,930 | $25M | 6.1% | ADD 10% |
| 4 | AMLXAMYLYX PHARMACEUTICALS INC | 1,750,000 | $24M | 6.0% | HOLD |
| 5 | NKTRNEKTAR THERAPEUTICS | 316,453 | $23M | 5.6% | ADD 50% |
| 6 | SLGLSOL GEL TECHNOLOGIES | 274,363 | $22M | 5.3% | NEW |
| 7 | ALMSALUMIS INC | 856,061 | $19M | 4.6% | NEW |
| 8 | DRUGBRIGHT MINDS BIOSCIENCES INC | 220,000 | $16M | 3.9% | NEW |
| 9 | ANNXANNEXON INC | 2,500,000 | $14M | 3.4% | NEW |
| 10 | KALVISTA PHARMACEUTICALS INC | 675,000 | $14M | 3.3% | HOLD |
| 11 | IMVTIMMUNOVANT INC | 545,625 | $14M | 3.3% | TRIM −27% |
| 12 | JBIOJADE BIOSCIENCES INC | 964,462 | $14M | 3.3% | ADD 20% |
| 13 | CTNMCONTINEUM THERAPEUTICS INC | 800,198 | $10M | 2.6% | HOLD |
| 14 | ZBIOZENAS BIOPHARMA INC | 524,066 | $10M | 2.5% | NEW |
| 15 | NGNENEUROGENE INC | 500,000 | $10M | 2.5% | ADD 43% |
| 16 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 500,000 | $9M | 2.3% | NEW |
| 17 | CLYMCLIMB BIO INC | 1,334,130 | $9M | 2.2% | ADD 36% |
| 18 | ORKAORUKA THERAPEUTICS INC | 183,330 | $9M | 2.2% | HOLD |
| 19 | EPRXEupraxia Pharmaceuticals Inc | 1,200,000 | $9M | 2.1% | HOLD |
| 20 | VERAVERA THERAPEUTICS INC | 199,348 | $8M | 2.0% | NEW |
| 21 | EVMNEVOMMUNE INC | 325,000 | $7M | 1.8% | HOLD |
| 22 | LBRXLB PHARMACEUTICALS INC | 300,000 | $7M | 1.8% | NEW |
| 23 | CMPXCOMPASS THERAPEUTICS INC | 1,350,000 | $7M | 1.7% | NEW |
| 24 | SCYXSCYNEXIS INC | 7,554,347 | $7M | 1.7% | NEW |
| 25 | PALIPALISADE BIO INC | 3,405,757 | $6M | 1.5% | NEW |
| 26 | CNTXCONTEXT THERAPEUTICS INC | 2,238,496 | $6M | 1.4% | TRIM −52% |
| 27 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $6M | 1.4% | NEW |
| 28 | SLNSILENCE THERAPEUTICS PLC | 1,020,489 | $5M | 1.3% | ADD 26% |
| 29 | UNCYUNICYCIVE THERAPEUTICS INC | 796,558 | $5M | 1.3% | HOLD |
| 30 | TENXTENAX THERAPEUTICS INC | 327,307 | $5M | 1.3% | NEW |
| 31 | PMNPROMIS NEUROSCIENCES INC | 371,402 | $5M | 1.2% | NEW |
| 32 | CGEMCULLINAN THERAPEUTICS INC | 300,000 | $4M | 1.0% | TRIM −53% |
| 33 | IMMXIMMIX BIOPHARMA INC | 350,000 | $3M | 0.8% | NEW |
| 34 | RZLTREZOLUTE INC | 951,809 | $3M | 0.7% | HOLD |
| 35 | PHVSPHARVARIS N V | 82,800 | $2M | 0.6% | HOLD |
| 36 | HUMAHUMACYTE INC | 3,750,000 | $2M | 0.6% | NEW |
| 37 | AVTXAVALO THERAPEUTICS INC | 124,666 | $2M | 0.5% | HOLD |
| 38 | ALKSALKERMES PLC | 50,000 | $2M | 0.4% | NEW |
| 39 | IRDOPUS GENETICS INC | 324,340 | $1M | 0.4% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| APGEAPOGEE THERAPEUTICS INC | — | — | — | 304K | 374K | 374K | $31M |
| VORVOR BIOPHARMA INC | — | — | — | — | 1.4M | 1.8M | $31M |
| ZURAZURA BIO LTD | 3.2M | 3.2M | 3.2M | 3.8M | 3.8M | 4.2M | $25M |
| AMLXAMYLYX PHARMACEUTICALS INC | — | 1.8M | 2.0M | 1.7M | 1.8M | 1.8M | $24M |
| NKTRNEKTAR THERAPEUTICS | — | — | — | 300K | 211K | 316K | $23M |
| SLGLSOL GEL TECHNOLOGIES | — | — | — | — | — | 274K | $22M |
| ALMSALUMIS INC | — | — | — | — | — | 856K | $19M |
| DRUGBRIGHT MINDS BIOSCIENCES INC | — | — | — | — | — | 220K | $16M |
| ANNXANNEXON INC | — | — | — | — | — | 2.5M | $14M |
| KALVISTA PHARMACEUTICALS INC | 1.8M | 1.0M | 323K | — | 686K | 675K | $14M |
| IMVTIMMUNOVANT INC | — | 375K | 262K | 500K | 750K | 546K | $14M |
| JBIOJADE BIOSCIENCES INC | — | — | 498K | 633K | 806K | 964K | $14M |
| CTNMCONTINEUM THERAPEUTICS INC | — | — | — | — | 800K | 800K | $10M |
| ZBIOZENAS BIOPHARMA INC | — | — | — | — | — | 524K | $10M |
| NGNENEUROGENE INC | 443K | 471K | 486K | 447K | 350K | 500K | $10M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
